Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Improving post-surgical management of resected pancreatic cancer

We read with interest the results of the ESPAC-4 trial and congratulate John Neoptolemos and colleagues (March 11, p 1011)1 on having done this challenging investigation. On the basis of overall survival, the primary study endpoint, ESPAC-4 was a positive trial favouring the gemcitabine plus capecitabine group more than the gemcitabine monotherapy group (hazard ratio [HR] 0·82, 95% CI 0·68–0·98; p=0·032). However, in contrast to other previous randomised trials in the adjuvant setting, the secondary endpoint—ie, relapse-free survival—was not different between the two comparator groups (HR 0·86, 0·73–1·02; p=0·082).

email